Back to results
US 9,308,202 B2Granted
Transdermal therapeutic system for administering the active substance buprenorphine
AssigneePurdue Pharma L.P.
InventorsThomas Hille, Michael Horstmann, Walter Mueller
Life of this patent
Estimating the term…
Abstract
The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance.
Claims20
A transdermal therapeutic system for administering buprenorphine to the skin, comprising:
- an active-ingredient-impermeable backing layer;
- at least one pressure-sensitive adhesive matrix layer comprising the active ingredient buprenorphine and laevulinic acid;
- wherein the matrix layer comprises a polymer selected from polysiloxanes or polyisobutylene;
- wherein the buprenorphine is dissolved in the laevulinic acid to form a solution and
- wherein the solution is dispersed, in the form of droplets, in the matrix layer.
2 more elements
A method of treating pain which comprises:
- administering to a patient, in need thereof, a transdermal therapeutic system for administering buprenorphine to the skin, wherein the transdermal therapeutic system comprises:
- an active-ingredient-impermeable backing layer;
- at least one pressure-sensitive adhesive matrix layer comprising a therapeutically effective amount of the active ingredient buprenorphine and laevulinic acid;
- wherein the matrix layer comprises a polymer selected from polysiloxanes or polyisobutylene;
- wherein the buprenorphine is dissolved in the laevulinic acid to form a solution;
- and
- wherein the solution is dispersed, in the form of droplets, in the matrix layer.
4 more elements
Dependencies are inferred from the claim text.